Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1187P is a processed pseudogene derived from the U6 small nuclear RNA (U6 snRNA) gene[2][4]. U6 snRNA itself plays a crucial role in the spliceosome complex, mediating pre-mRNA splicing in eukaryotic cells[1][3]. However, RNU6-1187P represents a genomic copy generated through retrotransposition events (often LINE-1 mediated) and typically lacks biological activity—it does not produce a functional RNA or protein[4]. These pseudogenes serve as markers of retrotransposition dynamics in the genome, reflecting the history of mobile genetic elements rather than functional gene products[4].\nIn summary, RNU6-1187P is not a therapeutic target, functional receptor, enzyme, transporter, or a disease marker, but rather a remnant of genomic evolution without direct molecular or pathological significance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1187, pseudogene (RNU6-1187P).